<DOC>
	<DOCNO>NCT00934557</DOCNO>
	<brief_summary>Paediatric patient affect haematological malignancy eligible undergo HSCT unrelated volunteer stratify accord degree compatibility donor , source haematopoietic stem cell employ ( BM vs. PB ) disease phase ( good vs. poor prognosis ) . In particular , basis compatibility donor , patient allocate 2 different arm : transplant unrelated donor either perfectly match single allelic disparity one HLA locus ( i.e . A , B , C , DrB1 ) vs. transplant unrelated donor either 2 allelic disparity antigenic disparity HLA locus ( i.e . A , B , C , DrB1 ) . Patients enrol study randomize receive ATG ( Fresenius ) dosage either 30 mg/Kg ( 10 mg/Kg day -4 , -3 -2 ) 15 mg/Kg ( 5 mg/Kg day -4 , -3 -2 ) . Good prognosis patient define follow : ALL 1st CR ; ALL 2nd CR belong S2 group ; AML 1st CR , AML 2nd CR relapse 6 month stop therapy ; NHL 2nd CR ; Ph+ CML 1st CP ; refractory cytopenia . Poor prognosis patient define follow : ALL 2nd CR belong S3-S4 group ; ALL ≥ 3rd CR ; AML 2nd CR relapse less 6 month stop therapy ; secondary AML ; NHL 3rd CR ; Ph+ CML 2nd CP , well AP ; RAEB , RAEB-t , JMML .</brief_summary>
	<brief_title>Randomized Study ATG Graft Versus Host Disease ( GVHD ) Prevention Paediatric Patients Given Unrelated Donor Stem Cell Transplantation</brief_title>
	<detailed_description>Study rationale Several report document patient give HSCT unrelated volunteer : - Increased incidence severity acute GVHD ; - Increased incidence severity chronic GVHD ; - Increased incidence graft rejection ; - Increased risk transplant-related death . The use anti-thymocyte globulin ( ATG ) demonstrate modulate alloreactivity T-lymphocytes , reduce risk post-transplant immune complication , namely graft rejection GVHD . However , concern use ATG exist , particular refer increased incidence severity infectious complication , increase risk malignancy recurrence increase risk EBV-related PTLD . Design study Paediatric patient affect haematological malignancy eligible undergo HSCT unrelated volunteer stratify accord degree compatibility donor , source haematopoietic stem cell employ ( BM vs. PB ) disease phase ( good vs. poor prognosis ) . In particular , basis compatibility donor , patient allocate 2 different arm : transplant unrelated donor either perfectly match single allelic disparity one HLA locus ( i.e . A , B , C , DrB1 ) vs. transplant unrelated donor either 2 allelic disparity antigenic disparity HLA locus ( i.e . A , B , C , DrB1 ) . Patients enrol study randomize receive ATG ( Fresenius ) dosage either 30 mg/Kg ( 10 mg/Kg day -4 , -3 -2 ) 15 mg/Kg ( 5 mg/Kg day -4 , -3 -2 ) . Good prognosis patient define follow : ALL 1st CR ; ALL 2nd CR belong S2 group ; AML 1st CR , AML 2nd CR relapse 6 month stop therapy ; NHL 2nd CR ; Ph+ CML 1st CP ; refractory cytopenia . Poor prognosis patient define follow : ALL 2nd CR belong S3-S4 group ; ALL ≥ 3rd CR ; AML 2nd CR relapse less 6 month stop therapy ; secondary AML ; NHL 3rd CR ; Ph+ CML 2nd CP , well AP ; RAEB , RAEB-t , JMML . Primary end-points • To evaluate influence different ATG dosage incidence severity acute GVHD . In particular , expect incidence 50 % acute grade II-IV GVHD low dosage ( 15 mg/Kg ) arm , whereas expect incidence 25 % high dosage ( 30 mg/Kg ) arm . Secondary end-points - To compare incidence chronic GVHD 2 ATG dosage arm . - To compare relapse rate 2 ATG dosage arm . - To compare TRM 2 ATG dosage arm . - To compare EFS 2 ATG dosage arm - To compare incidence EBV reactivation EBV-related post-transplant lymphoproliferative disorder 2 ATG dosage arm . - To compare incidence CMV reactivation 2 ATG dosage arm . - To compare incidence adenovirus infection 2 ATG dosage arm . - To compare incidence fungal infection 2 ATG dosage arm . Study population Patients enrol study affect : - ALL 1st , 2nd 3rd CR ; - AML 1st 2nd CR ; - NHL 2nd 3rd CR ; - Ph+ CML 1st 2nd CP , well AP ; - Refractory cytopenia , RAEB , RAEB-t , JMML . Inclusion criterion - Unrelated donor select use high-resolution molecular type HLA-A , B , C DrB1 locus , perfectly match single allelic disparity one HLA loci 2 allelic disparity antigenic disparity HLA locus ; - Age comprise 0 19 year ; - Life-expectancy least 2 month ; - Use G-CSF mobilized PB- BM-derived haematopoietic stem cell Exclusion criterion - Unrelated donor select use high-resolution molecular type HLA-A , B , C DrB1 locus , one antigenic disparity 2 allelic disparity HLA locus ; - Previous allogeneic HSCT ; - Cord blood source haematopoietic stem cell ; - Previous treatment rabbit ATG last 3 month HSCT ; - History allergic reaction rabbit ATG ; - Absence write informed consent . Stopping rule - 30 % mortality due acute GVHD within first 10 20 patient enrol 15 mg/Kg arm ; - 80 % incidence grade II-IV acute GVHD within first 10 20 patient enrol 15 mg/Kg arm ; - 30 % fatal infection ( virus and/or fungi ) within first 10 20 patient enrol 30 mg/Kg arm ; - 50 % relapse rate within first 10 20 patient enrol 30 mg/Kg arm ; - 80 % CMV reactivation within first 10 20 patient enrol 30 mg/Kg arm ; - 50 % EBV reactivation within first 10 20 patient enrol 30 mg/Kg arm ; - 30 % adenovirus reactivation within first 10 20 patient enrol 30 mg/Kg arm . GVHD prophylaxis All patient receive combination : cyclosporine-A ( Cs-A 3 mg/kg/day intravenously start day -2 ) short-term methotrexate ( MTX , 10 mg/m2 day +1 , +3 , +6 , +11 ) GVHD prophylaxis . Study sample Patient randomization perform coordinate study centre Pavia ; Dr. M. Zecca statistician responsible study . Patient enrolment calculate sample size evaluation method base log rank test estimate difference cumulative incidence grade II-IV acute GVHD . The minimum number patient randomize 80 per arm base significance level 0.05 , study power 0.80 , hypothesizing , child low dosage arm grade II-IV GVHD incidence 50 % child high dosage arm grade II-IV GVHD incidence 25 % . Interim analysis perform recruitment first 10 , 20 50 patient . Duration study Patients enrol approximately 24 month . Each patient must minimum observation time least 12 month . Thus , expect study duration 36 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Unrelated donor select use highresolution molecular typing HLAA , B , C DrB1 locus , perfectly match single allelic disparity one HLA loci 2 allelic disparity antigenic disparity HLA locus ; Age comprise 0 19 year ; Lifeexpectancy least 2 month ; Use GCSF mobilize PB BMderived haematopoietic stem cell Unrelated donor select use highresolution molecular typing HLAA , B , C DrB1 locus , one antigenic disparity 2 allelic disparity HLA locus ; Previous allogeneic HSCT ; Cord blood source haematopoietic stem cell ; Previous treatment rabbit ATG last 3 month HSCT ; History allergic reaction rabbit ATG ; Absence write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>